We have fine-tuned our forecasts for the current year. This plays a very minor role for Crossject since the story is that of the future market launches of the company’s NTEs (New Therapeutic Entities) as from FY25 and has no impact on our valuation. For the sake of detailing, the main difference with our previous FY24e EPS lies in a likely lower level of capitalised production than we expected for the full year, again with no consequences on the rest of our model.
